Feed excerpt — reported by ProPublica
Alicia Jackson endorsed a key FDA policy change on hormone replacement therapies while holding at least $115,000 in stock in a company providing access to menopause treatments. Ethics experts called her endorsement an “obvious conflict of interest.”
MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at ProPublica →